Annual General Meeting

The 18th Annual General Meeting took place on June 27, 2024 in Zurich. With the annual report, the management and Board of Directors of MetrioPharm AG provided an overview of the company's activities in the 2023 financial year.

Documents for the Annual General Meeting

Voting Results of the 18^th Annual General Meeting of MetrioPharm AG

Protocol of the 18^th Annual General Meeting of MetrioPharm AG (German only)

MetrioPharm AG Annual Report 2023

Statutes of MetrioPharm AG, November 2023 (German only)

Investor Relations

MetrioPharm Investor Relations News QIII 2024 - 2024-Sep-26

Mode of Action of MetrioPharm's Lead Molecule MP1032, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

Newsletter Subscription

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter